Tracking Down Response and Resistance to TRK Inhibitors

Cancer Discov. 2016 Jan;6(1):14-6. doi: 10.1158/2159-8290.CD-15-1352.

Abstract

Two recent studies validate the LMNA-NTRK1 fusion as an oncogenic driver and therapeutic target of TRK inhibitors. The LMNA-NTRK1 fusion occurs at low frequency across multiple tumor types. The studies highlight the increasing need to develop molecular biomarker-based clinical trials across cancer subtypes.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Brain Neoplasms / metabolism*
  • Brain Neoplasms / secondary
  • Chemokine CCL2 / antagonists & inhibitors
  • Chemokine CCL2 / metabolism
  • Drug Resistance, Neoplasm* / drug effects
  • Humans
  • Organ Specificity
  • PTEN Phosphohydrolase / deficiency*
  • Protein Kinase Inhibitors / pharmacology*
  • Protein Kinase Inhibitors / therapeutic use
  • Small Molecule Libraries / pharmacology
  • Small Molecule Libraries / therapeutic use
  • Tumor Microenvironment

Substances

  • CCL2 protein, human
  • Chemokine CCL2
  • Protein Kinase Inhibitors
  • Small Molecule Libraries
  • PTEN Phosphohydrolase
  • PTEN protein, human